Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Her2 Negative Breast Cancer Patients

In brief

To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone

Key facts

Study ID

NCT01151046

Run by

Merrimack Pharmaceuticals

People needed

118

Starts

2010-06-01

Expected to finish

2014-09-01

Last updated by the study team

2016-05-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced or metastatic breast cancer
• Histologically or cytologically confirmed ER+ and/or PgR+ and Her2 negative breast cancer
• ≥ 18 years of age

You may not qualify if…

• Received prior treatment with exemestane
• Extensive visceral disease (rapidly progressive, life-threatening metastases, including symptomatic lymphangitic metastases)
• Symptomatic CNS disease

Where it is running

• Achieve Clinical Research — Birmingham, Alabama, United States
• Achieve Clinical Research — Birmingham, Alabama, United States
• Arizona Center for Cancer Care — Glendale, Arizona, United States
• Pacific Cancer Medical Center — Anaheim, California, United States
• Beverly Hills Cancer Center — Beverly Hills, California, United States
• Wilshire Oncology Medical Group, Inc. — Corona, California, United States
• Southwest Cancer Center — Escondido, California, United States
• Hematology Oncology Associates, INC. — Oakland, California, United States
• San Jose Medical Center — San Jose, California, United States
• Central Coast Medical Oncology Corporation — Santa Maria, California, United States
• Pasco-Pinellas Oncology — New Port Richey, Florida, United States
• Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Indiana University Simon Cancer Center — Indianapolis, Indiana, United States
• Horizon Oncology Center — Lafayette, Indiana, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Tennessee Cancer Specialists Oncology Clinical Trials Center for Biomedical Research — Knoxville, Tennessee, United States
• Tennessee Cancer Specialists, Oncology Clincial Trials Center for Biomedical Research — Knoxville, Tennessee, United States
• Hopital Maissoneuve-Rosemont — Montreal, Quebec, Canada
• McGill University Jewish General Hospital — Montreal, Quebec, Canada
• Hopital du Sacre-Coeur de Montreal — Montreal, Canada
• CHA St. Sacrement — Québec, Canada
• Onkogologisches zentrum Munich — Munich, Germany
• Brustzentrum HS Kliniken Wiesbaden — Wiesbaden, Germany
• Medico-Diagnostically Center of International Institution of biological systems n.a.S.M. — Berezina, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.